Cytosorbents Corp (CTSO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cytosorbents Corporation is a medical device company focused on blood purification technologies, primarily through its CytoSorb device (approved in the EU) and the investigational DrugSorb-ATR (pending FDA approval). This report covers the quarterly period ended September 30, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $9.49 million | $8.61 million | $27.83 million | $26.44 million |
| Gross Profit | $6.67 million | $5.26 million | $19.69 million | $18.63 million |
| Gross Margin | 70.3% | 61.0% | 70.7% | 70.5% |
| Net Loss | $(3.17) million | $(2.77) million | $(2.70) million | $(13.15) million |
| Operating Loss | $(2.86) million | $(4.83) million | $(10.36) million | $(13.06) million |
| Cash & Equivalents (Unrestricted) | $7.54 million (as of Sept 30, 2025) | |||
| Total Debt (Long-Term) | $14.57 million (Principal $15.0M) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10.1% QoQ and 5.2% YoY (YTD), driven by strength in distributor/strategic partner sales and direct sales outside Germany, partially offset by lower revenue in the German market due to a commercial team realignment.
- Margin Expansion: Gross margin improved to 70.3% in Q3 2025 from 61.0% in Q3 2024, attributed to the resolution of prior-year manufacturing issues and production rebalancing.
- Expense Reduction: Operating expenses decreased 5.6% YoY (Q3) and 5.2% YoY (YTD). R&D expenses dropped 49.7% QoQ due to the completion of the STAR-T clinical trial and reduced grant-funded projects.
- Foreign Currency Impact: The Company recorded a $9.13 million gain on foreign currency transactions for the nine months ended Sept 30, 2025, compared to a $0.68 million gain in the prior year, significantly reducing the reported net loss. This was driven by the Euro strengthening against the USD.
- Capital Structure: The Company completed a Rights Offering in January 2025 raising $5.4 million net, and exercised Series A warrants in February 2025 raising an additional $1.4 million net. These proceeds released $5.0 million of restricted cash.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA denied the original DrugSorb-ATR De Novo application in April 2025 but affirmed no safety issues. The Company plans to file a new De Novo application in early 2026, with a decision expected in mid-2026. Health Canada review is paused pending FDA clarity.
- Cost Reduction Plan: On November 13, 2025, the Company announced a workforce reduction of approximately 10% and a cost reduction plan. Management expects to reach operating cash flow break-even in Q1 2026. A restructuring charge of up to $0.9 million is anticipated.
- Debt Amendment: The Company amended its loan with Avenue Capital Group to access an additional $2.5 million (Tranche 2a) in November 2025 and extended the interest-only period to December 31, 2026. A further $2.5 million (Tranche 2b) is available upon FDA approval of DrugSorb-ATR.
- Going Concern: The filing states that substantial doubt exists regarding the Company's ability to continue as a going concern within twelve months, despite the cost reduction plan and debt amendment, due to historical cash usage and capital requirements.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq's minimum bid price requirement (stock price below $1.00). It has a 180-day cure period to regain compliance by March 31, 2026.
- Internal Controls: A material weakness in internal controls over financial reporting was identified regarding the accounting for non-cash stock-based compensation (RSUs). Remediation is underway.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.54 million unrestricted cash balance against the burn rate post-restructuring and the timing of the Tranche 2a debt drawdown.
- Regulatory Timeline: Monitor the status of the new DrugSorb-ATR De Novo submission in early 2026 and the impact of the mid-2026 decision on Tranche 2b funding.
- Nasdaq Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the March 31, 2026 deadline to avoid delisting.
- German Market Recovery: Assess the effectiveness of the German commercial team realignment in reversing the revenue decline in that key territory.
- Restructuring Costs: Confirm the actual magnitude of the $0.9 million restructuring charge and its impact on Q4 2025 results.